These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 18956656)
1. [Updates on molecular markers of prostatic cancer]. Chang B; Li F; Song LJ Zhonghua Bing Li Xue Za Zhi; 2008 May; 37(5):339-41. PubMed ID: 18956656 [No Abstract] [Full Text] [Related]
2. [Alpha-methylacyl-CoA racemase: a useful marker for diagnosis of prostatic carcinoma]. Jiang Z; Ma K; Wu CL; Yang XJ Zhonghua Bing Li Xue Za Zhi; 2004 Oct; 33(5):401-3. PubMed ID: 15498205 [No Abstract] [Full Text] [Related]
3. Prostate cancer and the PCP: the screening dilemma. Rosenberg MT; Spring AC; David Crawford E Int J Clin Pract; 2015 Dec; 69(12):1438-47. PubMed ID: 26459772 [No Abstract] [Full Text] [Related]
4. Beyond PSA: a need for additional markers for prostate cancer. Sartor O Clin Prostate Cancer; 2004 Dec; 3(3):135. PubMed ID: 15636677 [No Abstract] [Full Text] [Related]
5. Advances in radiotherapy for prostate cancer. Ash D Br J Radiol; 2005; 78 Spec No 2():S112-6. PubMed ID: 16306633 [No Abstract] [Full Text] [Related]
6. [Immunohistochemical detection of prostate carcinoma]. Ma WX; Li W Zhonghua Bing Li Xue Za Zhi; 1989 Mar; 18(1):37-9. PubMed ID: 2476252 [TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor I and prostate cancer. O'Brien MF; Watson RW; Fitzpatrick JM Urology; 2001 Jul; 58(1):1-7. PubMed ID: 11445469 [No Abstract] [Full Text] [Related]
8. Markers of dispute. Hughes V Nat Med; 2009 Dec; 15(12):1339-43. PubMed ID: 19966757 [No Abstract] [Full Text] [Related]
9. The role of molecular biology in detection and monitoring of prostate cancer. Zummerová A; Böhmer D; Fillo J; Danihel L; Repiská V Cesk Patol; 2010 Oct; 46(4):95-7. PubMed ID: 21309265 [TBL] [Abstract][Full Text] [Related]
10. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy. De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485 [TBL] [Abstract][Full Text] [Related]
11. The importance of tumour marker dual reporting during method transition: PSA high-dose hook effect detected. Kittanakom S; Donohue V; Beattie J; Clark L; Kavsak PA Clin Biochem; 2018 Nov; 61():45-46. PubMed ID: 30179593 [No Abstract] [Full Text] [Related]
12. Defining the ideal tumor marker for prostate cancer. Montie JE; Meyers SE Urol Clin North Am; 1997 May; 24(2):247-52. PubMed ID: 9126220 [TBL] [Abstract][Full Text] [Related]
13. Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. Hsieh WS; Simons JW Cancer Treat Rev; 1993 Jul; 19(3):229-60. PubMed ID: 7687519 [No Abstract] [Full Text] [Related]
14. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Lin DW Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121 [TBL] [Abstract][Full Text] [Related]